← Back

Standard Biotools Inc

Standard BioTools Inc., together with its subsidiaries, develops, manufactures, and sells a range of instrumentation, consumables, and services to scientists and biomedical researchers to develop therapeutics in the Americas, Europe, the Middle East, Africa, and the Asia pacific. The company operates through Proteomics and Genomics segments. Its proteomics and genomics include instruments, consumables, and assays for clinical and diagnostic uses. The company also provides SomaScan platform that enables researchers to measure proteins simultaneously and provides deep insights into biological processes and disease mechanisms; CyTOF technology platform that uses metal-tagged antibodies and time-of-flight mass spectrometry to eliminate signal interference and expand multiplexing capabilities; Hyperion, a spatial biology platform, which unlocks deeper insights into tissue organization by preserving spatial context while enabling high-dimensional molecular and proteomic analysis; and Biomark X9 system that redefines high-throughput genomics for quantitative polymerase chain reaction applications. The company sells its instruments and consumables for research use only to academic research institutions, translational research and medicine centers, cancer centers, and clinical research laboratories, as well as biopharmaceutical, biotechnology, and plant and animal research companies. It has license agreements with California Institute of Technology, Harvard University, and Caliper Life Sciences, Inc. The company was formerly known as Fluidigm Corporation and changed its name to Standard BioTools Inc. in November 2001. Standard BioTools Inc. was incorporated in 1999 and is headquartered in Boston, Massachusetts.

Price · split & dividend adjusted
News & notes moving LAB
LAB▼

Standard BioTools posts $20.1 million in Q2 revenue, adjusted EBITDA loss narrows 84%

Standard BioTools reported second-quarter 2026 revenue of $20.1 million, a 7.6% decline from the prior year, while its adjusted EBITDA loss improved 84% to $2.5 million. The company said its merger with Treeline Biosciences is progressing toward a stockholder vote and is expected to close before year-end 2026. Operating expenses fell 1% to $35.9 million, though the net loss from continuing operations widened to $21.5 million, partly due to one-time transaction costs. Standard BioTools also withdrew its full-year 2026 revenue outlook because of the pending merger.
LAB ▼
GlobeNewswire·21dRead more ▾
LAB▲

Standard BioTools files registration statement for all-stock merger with Treeline Biosciences

Standard BioTools has filed a registration statement with the SEC for its all-stock merger with Treeline Biosciences, a clinical-stage biopharma company. The combined company is expected to have over $900 million in pro-forma cash at closing, which is anticipated in the second half of 2026, and will operate as Treeline Biosciences Holdings under the ticker TRLN. The filing highlights Treeline's pipeline, including headline Phase 1 monotherapy data for TLN-121 in relapsed or refractory lymphomas showing an 84% overall response rate and a 32% complete response rate with no dose-limiting toxicities. Interim data readouts for TLN-121 and TLN-372 are planned for 2027. Treeline also announced that Sue Desmond-Hellmann, former CEO of the Bill & Melinda Gates Foundation, has joined its Board of Directors.
LAB ▲
GlobeNewswire·37dRead more ▾
LAB

Brodsky & Smith investigates boards of AstroNova, Open Lending, Huntsman, and Standard BioTools over merger deals

Brodsky & Smith is investigating potential fiduciary duty breaches by the boards of four companies in connection with their announced mergers. AstroNova is being acquired by Arcline Investment Management for $29.00 per share in an all-cash deal valued at approximately $272 million. Open Lending is being acquired by ANV Group Holdings for $3.15 per share. Huntsman is being acquired by Olin Corporation, with Huntsman shareholders receiving 0.5476 Olin shares for each Huntsman share, resulting in Huntsman shareholders owning about 45.5% of the combined company. Standard BioTools is being acquired by Treeline Biosciences, with pre-merger Standard BioTools stockholders expected to own approximately 16% of the combined company. The investigations focus on whether the boards failed to conduct a fair process and whether the deal consideration provides fair value to shareholders.
ALOT HUN LAB LPRO OLN
GlobeNewswire·68dRead more ▾
© 2026 MarketDXAsset